Abstract
The FDA has approved Seglentis (Esteve/Kowa), an oral combination of tramadol hydrochloride, a weak opioid agonist and weak serotonin and norepinephri......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
